Immuneed

Our technology, ID.Flow, utilizes freshly donated human blood to help researchers better understand drug-induced immune reactions during non-clinical development. By improving the accuracy and relevance of safety and efficacy assessments, we reduce the need for animal studies and enhance the translatability of preclinical findings

Immunotoxicity,drug development,monoclonal antibodies,immune complexes,contract research organization,cytokine release assay,safety assessment,moa,functional studies,biologics,proteins,peptides,small molecules,complement activation,innate immunity,in-vitro immunotoxicity,immune profiling,immuno-oncology,platelet activation,monocyte activation,adcc & cdc assays,and non-clinical

Immuneed operates in the Research services industry.

Immuneed's revenue is 11m - 100m

Immuneed has 11 - 50 employees.